Skip to main content
. 2018 May 11;9(36):24548–24560. doi: 10.18632/oncotarget.24647

Figure 6. The efficacy evaluation of apatinib in two retrospective studies in patients with advanced sarcoma.

Figure 6

(A) Kaplan-Meier estimates of progression free survival (PFS). (B) Kaplan-Meier estimates of overall survival (OS). (C) Kaplan-Meier estimates of progression free survival (PFS). (Cited from: Zhu B, Li J, Xie Q, Diao L, Gai L, Yang W. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2017: 0. doi: 10.1080/15384047.2017.1416275; Li F, Liao Z, Zhao J, Zhao G, Li X, Du X, et al.. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017. doi: 10.18632/oncotarget.16293.)